(IN BRIEF) The European Investment Bank and Angelini Ventures have signed a €150 million funding agreement to support early- and growth-stage European startups in biotechnology, medical technology, and digital health. Each partner will invest €75 million over six years in … Read the full press release
Posted in Banks, European Union, Financial, Healthcare, Infrastructure & Utilities, Investment, Italy, Luxembourg, News, Small Business
Tagged ADCs, Adcytherix, Angelini Industries, Angelini Ventures, antibody-drug conjugates, biotechnology, corporate venture capital, deeptech, digital health, EIB, EIB Partners with Angelini Ventures to Back High-Impact Healthcare Startups and Boost Europe’s Technological Competitiveness, EU competitiveness, European Innovation, European venture capital, Gelsomina Vigliotti, life sciences, medtech, Paolo Di Giorgio, scale-up, Sergio Marullo di Condojanni, startup financing, TechEU, €150 million investment
(IN BRIEF) The German Research Center for Artificial Intelligence (DFKI) and Mainz University Medical Center have initiated the MARK project to understand and predict the biological aging of the immune system using artificial intelligence. Funded by the Rhineland-Palatinate Ministry of … Read the full press release
Posted in Artificial Intelligence (AI), Business, Education, Environment, Germany, Healthcare, News, Pharma & Biotech, Science, Society, Technology
Tagged aging research, AI in medicine, Andreas Dengel, artificial intelligence, biotechnology, blood stem cells, Center for Thrombosis and Hemostasis, Clemens Hoch, data science, DFKI, DFKI and Mainz researchers pioneer AI-driven insights into immune decline and age-related health risks, Germany, healthy aging, immune system aging, Kaiserslautern, life sciences, Mainz, Mainz University Medical Center, MARK project, MARK project combines artificial intelligence and biotechnology to advance healthy aging research in Rhineland-Palatinate, Molecular Analysis of Age-Related Risk Mechanisms, predictive health models, Rhineland-Palatinate Ministry of Science and Health, Wolfram Ruf
(IN BRIEF) Boehringer Ingelheim and CDR-Life have expanded their partnership through a global licensing agreement to develop CDR111, a trispecific M-gager® antibody designed to reset the immune system by selectively targeting B cells. The collaboration builds upon their prior success … Read the full press release
Posted in Business, Germany, Healthcare, Investment, News, Pharma & Biotech, Science, Switzerland, Technology
Tagged antibody-based therapy, Arthritis, autoimmune diseases, B cells, biotechnology, Boehringer Ingelheim, Boehringer Ingelheim and CDR-Life Expand Partnership with New Global Licensing Deal to Advance Autoimmune Disease Therapies, Carine Boustany, CDR-Life, CDR111, Christian Leisner, Geographic Atrophy, global licensing agreement, immune system reset, lupus, multiple sclerosis, pharmaceutical collaboration, T-cell engager, trispecific M-gager, USD 570 million deal, VERDANT Phase 2 trial
(IN BRIEF) The European Investment Bank (EIB) has provided a €20 million loan to Overture Life to develop automated and AI-driven technologies for in vitro fertilization (IVF) and egg freezing. The funding supports the company’s R&D, production expansion, and clinical … Read the full press release
Posted in Artificial Intelligence (AI), Banks, European Union, Financial, Healthcare, Investment, Luxembourg, News, Pharma & Biotech, Science, Spain, Technology
Tagged AI in healthcare, Bio-Europe 2025, biotechnology, DaVitri platform, EIB, EIB Backs Overture Life’s Innovation to Make IVF More Efficient and Widely Available through AI, EIB Invests €20 Million in Overture Life to Advance AI-Based Fertility and IVF Technologies, European Innovation, European Investment Bank, fertility preservation, fertility technology, Hans Gangeskar, healthcare digitalisation, innovation funding, InvestEU, IVF automation, Karl Nehammer, life sciences, Overture Life, reproductive health, TechEU, Vienna, Women’s Health
(IN BRIEF) Boehringer Ingelheim has licensed a pre-clinical small molecule program from Kyowa Kirin to develop a potential first-in-class therapy for autoimmune diseases, a major global health challenge affecting around 10% of the population. The deal grants Boehringer exclusive worldwide … Read the full press release
Posted in Business, Financial, Germany, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Technology
Tagged autoimmune diseases, biotechnology, Boehringer Ingelheim, Boehringer Ingelheim Secures Exclusive Global Rights to Develop New Autoimmune Treatment from Kyowa Kirin, Boehringer Ingelheim Strengthens Autoimmune Disease Pipeline with Licensing Agreement from Kyowa Kirin, Carine Boustany, chronic inflammation, drug development, global health, immunology, inflammatory diseases, Kyowa Kirin, licensing agreement, pharmaceutical innovation, pre-clinical program, respiratory diseases, small molecule therapy, Takeyoshi Yamashita
(IN BRIEF) Causeway Therapeutics, a University of Glasgow spin-out, has announced strong Phase 2 results for its novel microRNA therapy, TenoMiR®, used to treat tennis elbow. The study, involving 123 patients across the UK and USA, showed significant improvements in … Read the full press release
Posted in Education, Healthcare, Industrial, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged biotechnology, Causeway Therapeutics, Causeway Therapeutics Advances TenoMiR® Development Following Strong Phase 2 Results, clinical research, Declan Doogan, Derek Gilchrist, Glasgow City Council, Glasgow Riverside Innovation District, Iain McInnes, lateral epicondylitis, microRNA therapy, miR29a, Neal Millar, orthopaedic innovation, phase 2 trial, Phase 3 development, Promising Clinical Data Propel Glasgow Biotech Causeway Therapeutics Toward Full Development of TenoMiR®, Scott Rodeo, Scottish Enterprise, tendinopathy, tendon regeneration, tennis elbow, TenoMiR, University of Glasgow
Pertussis cases surge: Over 60,000 reported in Europe; infants most at risk. Maternal vaccination expands: Finland, Norway, and UK updated pregnancy vaccine strategies. BioNet advances: Submitted recombinant pertussis vaccine to EMA; secured EU-GMP approval. Nasal vaccine progresses: ILiAD’s BPZE1 granted … Read the full press release
Posted in Denmark, European Union, Finland, France, Germany, Healthcare, Ireland, News, Norway, Pharma & Biotech, Science, United Kingdom
Tagged acellular pertussis vaccine, Adacel, antibody avidity, antigen dose, ASEAN, Bio Farma, BioNet, biotechnology, booster dose, Boostrix-IPV, BPZE1, certification, Chulalongkorn University, clinical trial, compliance, Dario Cresci, dTap, ECDC, EMA, EU-GMP, EU-GMP certification, EU/EEA, Europe Confronts Pertussis Resurgence as Infant Cases Rise Amid Falling Immunity and Vaccination Gaps, Europe Faces Pertussis Resurgence Amid Waning Immunity and Falling Maternal Vaccination Rates, European Medicines Agency, European Union, European Union Good Manufacturing Practice, Europe’s Pertussis Vaccine Market Opens to New Entrants as Demand Rises, From EU-GMP Certification to ASEAN Partnerships BioNet Broadens Its Global Vaccine Strategy, GMP production facilities, GSK, Hanna Nohynek, health policy, HPRA, human challenge trial, hVIVO, ILiAD Biotechnologies, immunization strategy, infant protection, Innovation Passport, Institut Pasteur, intranasal vaccine, Ireland Health Products Regulatory Authority, Lancet Infectious Diseases, maternal vaccination, MHRA, mucosal immunity, outbreak, pandemic recovery, Pertagen®, pertussis, pertussis vaccine, Pertussis Vaccine Manufacturing, pharmaceutical quality, Phase 3, Philippe Guillot-Chêne, pregnancy immunization, public health, recombinant pertussis vaccine, recombinant pertussis vaccines, regulatory approval, Sanofi, Tdap, TdaP combination vaccine, V, vaccine, vaccine blunting, vaccine development, Vaccine Hesitancy, vaccine pipeline, vaccine rollout, vaccine shortage, vaccine supply, vaccine uptake, VacPertagen, whooping cough
(IN BRIEF) Brenntag has signed an exclusive European distribution agreement with ArcticZymes AS for its line of salt-active nucleases—SAN HQ, SAN-HQ GMP, M-SAN HQ, and M-SAN HQ GMP—used in gene therapy, vaccine manufacturing, and bioprocessing. Signed during the CPHI fair … Read the full press release
Posted in Business, Chemicals, Financial, Germany, Industrial, Management, Pharma & Biotech
Tagged ArcticZymes, biopharma, biopharmaceutical innovation, bioprocessing, biotechnology, Brenntag, Brenntag and ArcticZymes Join Forces to Support Growth in Biopharmaceutical and Gene Therapy Markets, CPHI Frankfurt, downstream processing, enzyme distribution, enzymes, European partnership, gene therapy, GMP, Joakim Rehné, life sciences, M-SAN HQ, nucleases, Paul Blackburn, SAN HQ, vaccine manufacturing
BioNet earns EU-GMP certification for its acellular pertussis vaccine, confirming compliance with EU manufacturing and quality standards. Inspection by Ireland’s HPRA supports EMA review of BioNet’s recombinant vaccine candidate VacPertagen. Partnerships expanding: MoU with Indonesia’s Bio Farma to accelerate TdaP … Read the full press release
Posted in European Union, France, Healthcare, Ireland, Pharma & Biotech, Science
Tagged acellular pertussis vaccine, BioNet, BioNet’s EU-GMP Certification Marks Strategic Step Toward EMA Review and Expands Global Vaccine Reach, BioNet’s Manufacturing Accreditation Aligns with Growing International Efforts to Reinforce Pertussis Vaccine Supply, biotechnology, certification, compliance, Dario Cresci, EMA, EU-GMP certification, European Medicines Agency, European Union, European Union Good Manufacturing Practice, From EU-GMP Certification to ASEAN Partnerships BioNet Broadens Its Global Vaccine Strategy, GMP production facilities, HPRA, Ireland Health Products Regulatory Authority, Pertagen®, pertussis, pertussis vaccine, Pertussis Vaccine Manufacturing, pharmaceutical quality, Philippe Guillot-Chêne, recombinant pertussis vaccines, Regulatory Milestone and Research Progress Signal BioNet’s Expanding Role in Next-Generation Vaccine Development, V, vaccine, VacPertagen
(IN BRIEF) BioNet has achieved European Union Good Manufacturing Practice (EU-GMP) certification, a key international standard that validates its facilities and processes for producing high-quality pharmaceuticals. This certification, granted after inspection by Ireland’s Health Products Regulatory Authority (HPRA), allows BioNet … Read the full press release
Posted in European Union, France, Healthcare, Ireland, Pharma & Biotech
Tagged acellular pertussis vaccine, BioNet, biotechnology, certification, compliance, Dario Cresci, EMA, EU-GMP certification, European Medicines Agency, European Union, European Union Good Manufacturing Practice, GMP production facilities, HPRA, Ireland Health Products Regulatory Authority, Pertagen®, pertussis, pertussis vaccine, Pertussis Vaccine Manufacturing, pharmaceutical quality, Philippe Guillot-Chêne, recombinant pertussis vaccines, vaccine, VacPertagen
(IN BRIEF) Novartis announced a definitive agreement to acquire Avidity Biosciences for USD 12 billion in cash, in a move that strengthens its neuroscience franchise and accelerates its xRNA therapeutic strategy. The acquisition brings Avidity’s late-stage programs in myotonic dystrophy … Read the full press release
Posted in Business, Healthcare, Investment, Pharma & Biotech, Switzerland
Tagged acquisition, Antibody Oligonucleotide Conjugates, AOCs, Avidity Biosciences, Basel, biopharma, biopharmaceutical innovation, biotechnology, clinical research, DM1, DMD, drug development, Duchenne muscular dystrophy, EXPLORE44 trial, facioscapulohumeral muscular dystrophy, FORTITUDE trial, FSHD, genetic medicine, HARBOR trial, muscle-directed therapy, myotonic dystrophy type 1, neuromuscular diseases, Novartis, Novartis Strengthens Neuroscience Franchise with Acquisition of Avidity Biosciences and Its Muscle-Directed RNA Platform, RNA delivery, RNA therapeutics, San Diego, SpinCo, Vas Narasimhan, xRNA strategy
(IN BRIEF) Evotec SE announced it has received a US$ 25 million payment from Bristol Myers Squibb, marking progress in their joint neuroscience partnership focused on neurodegenerative diseases. The milestone payment will further advance the companies’ preclinical pipeline and research … Read the full press release
Posted in Business, Germany, Healthcare, Investment, News, Pharma & Biotech, Science, Technology
Tagged biotechnology, BMS-986419, Bristol-Myers Squibb, clinical trials, Cord Dohrmann, disease-modifying therapies, drug discovery, Evotec and Bristol Myers Squibb Advance Neuroscience Collaboration with New Funding Milestone, Evotec SE, EVT8683, milestone payment, neurodegenerative diseases, neuroscience, neuroscience collaboration, neuroscience research, pharmaceutical innovation, preclinical research, strategic partnership, translational medicine
(IN BRIEF) Symrise has made a strategic equity investment in U.S.-based biotech firm Cellibre to drive innovation in sustainable biomanufacturing. The collaboration will accelerate the commercialization of natural flavor ingredients and cosmetic bioactives produced through precision fermentation. By combining Symrise’s … Read the full press release
Posted in Apparel, Fashion & Beauty, Chemicals, Food & Beverage, Germany, Marketing, Pharma & Biotech
Tagged Ben Chiarelli, biomanufacturing, biotechnology, biotechnology investment, Cellibre, Clean Beauty, corporate sustainability, cosmetic bioactives, environmental responsibility, fermentation-derived ingredients, food and beverage industry, global supply chain, Imke Meyer, natural flavors, nutraceuticals, Precision Fermentation, sustainable cosmetics, Sustainable Ingredients, sustainable innovation, Symrise, Symrise Partners with Cellibre to Accelerate Biotechnology Innovation in Natural Flavors and Cosmetic Actives, taste balancing
(IN BRIEF) Sanofi’s investigational therapy efdoralprin alfa met all primary and key secondary endpoints in the Phase 2 ElevAATe study for alpha-1 antitrypsin deficiency emphysema, demonstrating superior efficacy compared to standard plasma-derived therapy. The results highlight its potential as the … Read the full press release
Posted in France, Healthcare, Pharma & Biotech
Tagged AATD emphysema, alpha-1 antitrypsin deficiency, biotechnology, Christopher Corsico, clinical research, David Geffen School of Medicine, efdoralprin alfa, ElevAATe OLE, ElevAATe study, FDA Fast Track, functional AAT, Igor Barjaktarevic, orphan drug designation, phase 2 trial, protein replacement therapy, pulmonary medicine, rare disease, recombinant therapy, respiratory health, respiratory innovation, Sanofi, Sanofi’s Efdoralprin Alfa Shows Superior Results in Phase 2 AATD Emphysema Trial, SAR447537, UCLA
(IN BRIEF) BASF and International Flavors & Fragrances Inc. (IFF) have announced a strategic partnership to accelerate the development of next-generation enzyme technologies and biobased polymers for fabric, dish, personal care, and industrial cleaning applications. The collaboration combines BASF’s expertise … Read the full press release
Posted in Business, Chemicals, Germany, Industrial, Marketing, Technology
Tagged BASF, BASF and IFF advance sustainable chemistry with joint development of enzyme and polymer innovations, biobased polymers, bioscience, biotechnology, Chemical Industry, cleaning products, collaboration, Designed Enzymatic Biomaterials, eco-friendly solutions, enzyme technology, Erik Fyrwald, IFF, Industrial Cleaning, INNOVATION, International Flavors & Fragrances, Michael Heinz, personal care, protein engineering, Strategic alliance between BASF and IFF drives innovation in enzyme and biobased polymer technologies, sustainability, sustainable chemistry
(IN BRIEF) EDAP TMS SA has secured a €36 million credit facility from the European Investment Bank (EIB), supported by the European Commission’s InvestEU guarantee, to boost the global expansion of its Focal One® Robotic HIFU platform and fund new … Read the full press release
Posted in Banks, Financial, Healthcare, Investment, Luxembourg, News, Pharma & Biotech, Science, Technology
Tagged Ambroise Fayolle, biotechnology, credit facility, EDAP Strengthens Growth Strategy with EIB-Backed €36 Million Credit Facility for Non-Invasive Medical Technology Expansion, EDAP TMS, EIB, endometriosis, EU innovation support, European Investment Bank, European Investment Bank Backs EDAP TMS with €36 Million Credit Facility under InvestEU Program, Focal One, gynecology, Healthcare Innovation, high-intensity focused ultrasound, InvestEU, Lyon, medical technology, non-invasive therapy, prostate cancer, Robotic HIFU, Ryan Rhodes, SEC filing, urology
(IN BRIEF) The Nordic Investment Bank (NIB) has approved a EUR 50 million, 10-year loan to Kemira for constructing a new biomaterials production facility in Finland. The project, jointly developed with International Flavors & Fragrances (IFF), will produce bio-based alpha-glucans … Read the full press release
Posted in Banks, Business, Chemicals, Economy, Environment, Financial, Finland, Industrial, Investment, Management, News, Technology
Tagged alpha-glucans, André Küüsvek, bio-based production, biobased products, biomaterials, biotechnology, Chemical Industry, Finland, green finance, IFF, industrial innovation, International Flavors & Fragrances, Kemira, NIB, NIB Backs Kemira’s EUR 130 Million Investment in Renewable Biomaterials to Advance Finland’s Green Industry, NIB Provides EUR 50 Million Loan to Kemira for New Bio-Based Materials Plant in Finland, Nordic Investment Bank, Nordic-Baltic region, Petri Castrén, renewable materials, renewable solutions, sustainability, sustainable chemistry
(IN BRIEF) BASF’s Isobionics® has introduced Isobionics® Natural alpha-Farnesene 95, a high-purity natural flavor ingredient designed for lime oil and citrus applications. Produced through fermentation technology using renewable resources, the product ensures exceptional consistency, sustainability, and purity above 95%. It … Read the full press release
Posted in Chemicals, Food & Beverage, Netherlands, Technology
Tagged alpha-Farnesene 95, aroma ingredients, BASF, BASF Aroma Ingredients, BASF’s Isobionics® Expands Natural Aroma Portfolio with Launch of Isobionics® Natural alpha-Farnesene 95 for Lime Applications, beta-Bisabolene 90, beta-Caryophyllene 80, beverages, biotechnology, citrus flavors, EU food grade, FEMA 3839, fermentation technology, FLAVIS 01.040, FSSC 22000, Geleen Netherlands, Giovanni D’Andola, halal, high purity, Isobionics®, Isobionics® Strengthens BASF’s Aroma Ingredients Portfolio with Fermentation-Based Natural alpha-Farnesene 95 for Lime and Citrus Flavors, kosher, lime oil, natural flavor ingredients, renewable resources, Steffen Götz, sustainable production, sweets, trans-alpha-Bergamotene 80
(IN BRIEF) The European Investment Bank and European Commission are jointly supporting BioNTech’s mRNA manufacturing facility in Kigali, Rwanda, with up to €95 million in blended financing. The project aims to strengthen Africa’s capacity to produce vaccines locally for diseases … Read the full press release
Posted in Banks, European Union, Financial, Healthcare, Investment, Luxembourg, News, Pharma & Biotech, Technology
Tagged Africa CDC, African Union, and CEPI Join Forces to Strengthen Africa’s Vaccine Independence Through BioNTech’s Kigali mRNA Facility, BioNTech, BioNTech Secures up to €95 Million in EU and EIB Financing to Boost Vaccine Manufacturing Capacity in Kigali, biotechnology, CEPI, Dr Amadou Sall, EIB, EU, European Commission, European Investment Bank, Global Gateway, HIV, Jozef Sikela, Karl Nehammer, Kigali, local production, malaria, mpox, mRNA Vaccines, public health, Rwanda, Sierk Poetting, Sustainable Healthcare, Team Europe, tuberculosis, Vaccine Innovation, vaccine manufacturing
(IN BRIEF) The Fraunhofer-Gesellschaft has partnered with the Spanish government, Government of Catalonia, and city of Barcelona to establish a joint framework for advancing theranostics research in Spain — a field that combines diagnostics and therapy for personalized medicine. The … Read the full press release
Posted in Business, Germany, Government, News, Pharma & Biotech, Science, Spain, Technology
Tagged bioengineering, biomedical engineering, biotechnology, Catalonia, City of Barcelona, diagnostics, Diana Morant, Europe, Fraunhofer and Catalan Partners Establish Framework for Applied Theranostics Innovation, Fraunhofer and Spanish Partners Unite to Advance Theranostics and Personalized Medicine in Barcelona, Fraunhofer CAT, Fraunhofer Center for Applied Theranostics, Fraunhofer IBMT, Fraunhofer Spain Research Foundation, Fraunhofer-Gesellschaft, Government of Catalonia, Healthcare Innovation, Heiko Zimmermann, Holger Hanselka, IBEC, Jaume Collboni, Josep Samitier, life sciences, New Fraunhofer Initiative in Spain to Drive European Leadership in Theranostics Research, Núria Montserrat Pulido, personalized medicine, Peter Hauptmann, precision medicine, research collaboration, Salvador Illa, Spain and Germany Strengthen Research Ties Through New Fraunhofer Center for Theranostics in Barcelona, Spanish government, theranostics, therapy
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?